Ibuprofen
Ibuprofen MODAFEN contains the active substance ibuprofen, which belongs to a group of medicines called non-steroidal anti-inflammatory drugs (NSAIDs).
Ibuprofen MODAFEN is used for the symptomatic treatment of pain and inflammation in joint diseases (e.g., rheumatoid arthritis), degenerative joint diseases (e.g., osteoarthritis), and painful swellings and inflammation after soft tissue injuries.
Ibuprofen MODAFEN, 600 mg, coated tablets are indicated for use in adults and adolescents with a body weight of 50 kg or more (from 15 years of age).
Before taking Ibuprofen MODAFEN, discuss with your pharmacist or doctor:
The risk of side effects increases with increasing doses of the medicine and in elderly patients. Therefore, it is necessary to start treatment with the lowest possible dose and continue treatment for the shortest possible period necessary to alleviate symptoms.
Ibuprofen MODAFEN may mask the symptoms of infection, such as fever and pain. Therefore, it is possible that Ibuprofen MODAFEN may delay the use of appropriate infection treatment, which can lead to increased risk of complications. This has been observed in the course of pneumonia caused by bacteria and bacterial skin infections associated with chickenpox.
If the patient is taking this medicine during an infection, and the symptoms of the infection persist or worsen, they should consult a doctor immediately.
The use of anti-inflammatory/pain-relieving medicines, such as ibuprofen, may be associated with a slight increase in the risk of heart attack (myocardial infarction) or stroke, especially if they are used in high doses. Do not exceed the recommended dose or duration of treatment.
Before taking Ibuprofen MODAFEN, the patient should discuss their treatment with a doctor or pharmacist if:
It is recommended to avoid taking Ibuprofen MODAFEN with other non-steroidal anti-inflammatory drugs (NSAIDs), including so-called COX-2 inhibitors (cyclooxygenase-2 inhibitors).
Gastrointestinal bleeding, ulcers, and perforations:
With the use of all NSAIDs, gastrointestinal bleeding, ulcers, and perforations have been reported, sometimes fatal. They occurred at any time during treatment, with or without prior warning symptoms or serious gastrointestinal events in the medical history.
The risk of gastrointestinal bleeding, ulcers, and perforations is higher with increasing doses of NSAIDs and is higher in patients with a history of ulcers, especially with complications such as bleeding or perforation (see section 2 "When not to take Ibuprofen MODAFEN") and in elderly patients. These patients should start treatment with the lowest available dose. For these patients, as well as patients requiring additional treatment with low doses of acetylsalicylic acid or other medicines that may increase the risk of gastrointestinal disorders, concomitant treatment with protective medicines (e.g., misoprostol or proton pump inhibitors) should be considered.
Patients who have had gastrointestinal side effects in the past - especially the elderly - should consult a doctor if they experience unusual abdominal symptoms (especially gastrointestinal bleeding), especially at the beginning of treatment.
Care should be taken when taking other medicines that may increase the risk of ulcers or bleeding, such as oral corticosteroids, anticoagulants (blood thinners) such as warfarin, selective serotonin reuptake inhibitors (used to treat mental disorders, including depression), or antiplatelet agents such as acetylsalicylic acid (see section 2 "Ibuprofen MODAFEN and other medicines").
Treatment should be discontinued and a doctor consulted if gastrointestinal bleeding or ulcers occur during treatment with Ibuprofen MODAFEN.
Serious skin reactions have been reported with the use of Ibuprofen MODAFEN. The patient should stop taking Ibuprofen MODAFEN and seek medical help immediately if they experience a skin rash, changes in the mucous membranes, blisters, or other signs of an allergic reaction, as these may be the first signs of a very serious skin reaction. See section 4.
Other warnings
Very rare, severe, acute hypersensitivity reactions (e.g., anaphylactic shock) have been observed. If the patient experiences the first symptoms of a hypersensitivity reaction after taking Ibuprofen MODAFEN, treatment should be discontinued and a doctor consulted. Medical measures required according to the symptoms must be taken by a healthcare professional.
Ibuprofen may temporarily inhibit platelet function (platelet aggregation). Therefore, patients with bleeding disorders should be closely monitored.
Long-term use of any pain-relieving medicines for headaches may worsen them. If this occurs or is suspected, medical advice should be sought and treatment discontinued. Medication overuse headache (MOH) should be suspected in patients who experience frequent or daily headaches despite (or due to) regular use of pain-relieving medicines.
During long-term use of ibuprofen, regular monitoring of liver, kidney, and blood morphology is required.
In general, habitual use of pain-relieving medicines, especially in combination with several pain-relieving medicines, can lead to permanent kidney damage. This risk may be increased during physical exertion associated with salt loss and dehydration. Therefore, this should be avoided.
Dehydrated adolescents are at risk of kidney dysfunction.
Ibuprofen MODAFEN, 600 mg, coated tablets are not intended for adolescents with a body weight below 50 kg or children and adolescents under 15 years of age.
The patient should tell their doctor or pharmacist about all medicines they are currently taking or have recently taken, as well as any medicines they plan to take. Ibuprofen MODAFEN may affect the action of some other medicines or other medicines may affect its action.
For example:
Ibuprofen MODAFEN may affect the action of some other medicines or other medicines may affect its action. Therefore, before taking Ibuprofen MODAFEN with other medicines, the patient should always consult a doctor or pharmacist.
The patient should avoid consuming alcohol, as it may enhance the side effects of this medicine, especially those affecting the stomach, intestines, or brain.
If the patient is pregnant or breastfeeding, thinks they may be pregnant, or plans to have a child, they should consult a doctor before taking this medicine.
Pregnancy
Breastfeeding
Ibuprofen passes into breast milk in very small amounts and usually does not require stopping breastfeeding during short-term use of ibuprofen in the recommended dose for fever and pain. However, if long-term treatment or higher doses are recommended, breastfeeding should be discontinued.
Fertility
Ibuprofen MODAFEN may cause difficulty in getting pregnant. The patient should inform their doctor if they plan to get pregnant or are having trouble getting pregnant.
This medicine belongs to a group of medicines (NSAIDs) that may have a negative effect on female fertility. This effect is temporary and reverses after stopping the medicine.
Ibuprofen usually has no or negligible influence on the ability to drive and use machines. However, as higher doses may cause side effects from the central nervous system, such as fatigue and dizziness, the ability to react and participate in traffic or operate machinery may be impaired in individual cases. This is more likely when combined with alcohol.
This medicine contains less than 1 mmol (23 mg) of sodium per coated tablet, which means the medicine is essentially "sodium-free".
This medicine should always be taken as directed by the doctor. In case of doubt, consult a pharmacist or doctor.
The patient should take the smallest effective dose for the shortest possible period necessary to alleviate symptoms. In case of infection, they should consult a doctor immediately if symptoms (such as fever and pain) persist or worsen (see section 2).
DOSAGE:
The maximum single dose should not exceed 600 mg of ibuprofen for adults and adolescents with a body weight of 50 kg or more (from 15 years of age).
The recommended daily dose is 1200 mg-1800 mg in divided doses. There should be at least a 6-hour interval between doses. The doctor may recommend lower doses. Depending on the nature and severity of the patient's condition, the doctor may decide to increase the dose of the medicine to one 600 mg tablet, taken 4 times a day. The maximum daily dose should not exceed 2400 mg within 24 hours.
The recommended daily dose is 20 mg/kg body weight to a maximum of 40 mg/kg body weight, divided into 3-4 partial doses. There should be at least a 6-hour interval between doses. The maximum total daily dose should not exceed 2400 mg within 24 hours.
Use in children and adolescents
The dose of ibuprofen in adolescents depends on the patient's age and body weight.
Ibuprofen MODAFEN, 600 mg, coated tablets are not intended for adolescents with a body weight below 50 kg or children and adolescents under 15 years of age.
Elderly patients
Elderly patients should always consult a doctor before taking Ibuprofen MODAFEN. Elderly patients will be more prone to side effects, especially bleeding, ulcers, and perforation of the gastrointestinal tract, which can be fatal. The doctor will provide the patient with appropriate advice.
Reduced liver or kidney function
In case of reduced kidney or liver function, the patient should always consult a doctor before taking Ibuprofen MODAFEN. This medicine should not be taken if there is severe liver or kidney failure.
Method of administration
Ibuprofen MODAFEN is taken orally.
Tablets should be swallowed with a glass of water. Tablets should be swallowed whole, without chewing, crushing, breaking, or sucking, to prevent discomfort in the mouth or throat irritation.
Patients with sensitive stomachs are advised to take the tablets with food.
If the medicine is taken shortly after eating, the onset of action of ibuprofen may be delayed.
Duration of treatment:
The duration of treatment is determined by the doctor.
In the case of rheumatic diseases, it may be necessary to take Ibuprofen MODAFEN for a longer period.
In case of taking a higher dose of Ibuprofen MODAFEN than recommended or accidental ingestion by children, the patient should always consult a doctor or the nearest hospital for advice on the risk and actions to be taken.
Symptoms may include nausea, abdominal pain, vomiting (which may be bloody), or, less often, diarrhea. Additionally, there may be headache, gastrointestinal bleeding, blurred vision, ringing in the ears, disorientation, and nystagmus, as well as worsening of asthma in asthmatics. At high doses, drowsiness, excitement, disorientation, chest pain, palpitations, loss of consciousness, seizures (mainly in children), vertigo of labyrinthine origin, weakness, and vertigo have been reported.
A double dose should not be taken to make up for a missed dose.
In case of any further doubts about taking this medicine, the patient should consult a doctor or pharmacist.
Like all medicines, Ibuprofen MODAFEN can cause side effects, although not everybody gets them.
The patient can minimize the risk of side effects by taking the smallest effective dose for the shortest possible period necessary to alleviate symptoms.
Regarding the following side effects, it should be considered that they are largely dose-dependent and vary from patient to patient.
The most common side effects are gastrointestinal in nature. Stomach ulcers, perforation, or gastrointestinal bleeding may occur, sometimes leading to death, especially in elderly patients. After administration, nausea, vomiting, diarrhea, bloating, constipation, indigestion, abdominal pain, black stools, vomiting blood, oral ulceration, exacerbation of ulcerative colitis, and Crohn's disease have been reported. Less often, gastric mucosal inflammation has been observed.
The use of medicines such as ibuprofen may be associated with a slight increase in the risk of heart attack (myocardial infarction) or stroke. With the use of NSAIDs, fluid retention (edema), high blood pressure, and heart failure have been reported.
The patient should STOP TAKING Ibuprofen MODAFEN and consult a doctor immediately if they experience any of the following symptoms:
If side effects occur, including those not listed in this leaflet, the patient should tell their doctor or pharmacist. Side effects can be reported directly to the Department of Drug Safety Monitoring of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, phone: +48 22 49 21 301, fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder.
By reporting side effects, more information can be collected on the safety of this medicine.
The active substance of the medicine is ibuprofen. Each coated tablet contains 600 mg of ibuprofen.
The other ingredients are: tablet core - microcrystalline cellulose 102, maize starch paste, povidone K-90, sodium lauryl sulfate, croscarmellose sodium, colloidal anhydrous silica, magnesium stearate, tablet coating - hypromellose 2910, hydroxypropylcellulose, macrogol 400, titanium dioxide (E 171).
White or almost white, coated tablets in the shape of a capsule with the imprint "I 7" on one side and smooth on the other. The approximate dimensions of the tablet are 17.19 mm x 9.23 mm, thickness 6.60 mm.
Colorless, transparent blister pack made of PVC/Aluminum in an outer cardboard box containing 10 or 12 tablets in a blister pack.
Pack sizes:
20, 24, 30, 40, 50, 100 tablets.
Not all pack sizes may be marketed.
Marketing authorization holder:
STADA Arzneimittel AG
Stadastrasse 2-18
61118 Bad Vilbel
Germany
Importer:
Pharmazet Group s.r.o.
Třtinová 260/1
196 00 Prague 9
Czech Republic
Czech Republic:
Ibuprofen STADA 600 mg coated tablets
Spain:
Ibuprofeno Pharmaclan 600 mg film-coated tablets EFG
Germany:
Ibuprofen AL 600 mg film-coated tablets
France:
IBUPROFENE EG LABO 600 mg, film-coated tablet
Finland:
Ibuprofen Pharmaclan
Poland:
Ibuprofen MODAFEN
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.